Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.

Robertson AS, Majchrzak MJ, Smith CM, Gagnon RC, Devidze N, Banks GB, Little SC, Nabbie F, Bounous DI, DiPiero J, Jacobsen LK, Bristow LJ, Ahlijanian MK, Stimpson SA.

Neuromuscul Disord. 2017 Jul;27(7):635-645. doi: 10.1016/j.nmd.2017.05.009. Epub 2017 May 12.

2.

Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.

Wager TT, Chappie T, Horton D, Chandrasekaran RY, Samas B, Dunn-Sims ER, Hsu C, Nawreen N, Vanase-Frawley MA, O'Connor RE, Schmidt CJ, Dlugolenski K, Stratman NC, Majchrzak MJ, Kormos BL, Nguyen DP, Sawant-Basak A, Mead AN.

ACS Chem Neurosci. 2017 Jan 18;8(1):165-177. doi: 10.1021/acschemneuro.6b00297. Epub 2016 Oct 21.

PMID:
27715007
3.

Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing.

Modi ME, Majchrzak MJ, Fonseca KR, Doran A, Osgood S, Vanase-Frawley M, Feyfant E, McInnes H, Darvari R, Buhl DL, Kablaoui NM.

J Pharmacol Exp Ther. 2016 Aug;358(2):164-72. doi: 10.1124/jpet.116.232702. Epub 2016 May 23.

4.

Pharmacological disruption of mouse social approach behavior: relevance to negative symptoms of schizophrenia.

Hanks AN, Dlugolenski K, Hughes ZA, Seymour PA, Majchrzak MJ.

Behav Brain Res. 2013 Sep 1;252:405-14. doi: 10.1016/j.bbr.2013.06.017. Epub 2013 Jun 25.

PMID:
23806621
5.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

PMID:
22328573
6.

Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.

Strick CA, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ.

Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15. doi: 10.1016/j.neuropharm.2011.06.029. Epub 2011 Jul 7.

PMID:
21763704
7.

A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists.

Lowe JA 3rd, DeNinno SL, Coe JW, Zhang L, Mente S, Hurst RS, Mather RJ, Ward KM, Shrikhande A, Rollema H, Johnson DE, Horner W, Gorczyca R, Tingley FD 3rd, Kozak R, Majchrzak MJ, Tritto T, Sadlier J, Shaffer CL, Ellerbrock B, Osgood SM, MacDougall MC, McDowell LL.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4749-52. doi: 10.1016/j.bmcl.2010.06.142.

PMID:
20663668
8.

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE.

Biochem Pharmacol. 2009 Oct 1;78(7):813-24. doi: 10.1016/j.bcp.2009.05.033. Epub 2009 Jun 6.

PMID:
19501054
9.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
10.

Modern diagnostics of Chlamydia trachomatis infections.

Stańczak JJ, Majchrzak MJ, Stańczak GP.

Med Wieku Rozwoj. 2005 Jan-Mar;9(1):9-20. Review.

PMID:
16082060
11.

Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.

Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Prete Di CC, Lee JS, Trozzi A.

Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30.

PMID:
9871530
12.
13.

Effects of lobeline, a nicotinic receptor agonist, on learning and memory.

Decker MW, Majchrzak MJ, Arnerić SP.

Pharmacol Biochem Behav. 1993 Jul;45(3):571-6.

PMID:
8332618
14.

Effects of nicotine on spatial memory deficits in rats with septal lesions.

Decker MW, Majchrzak MJ, Anderson DJ.

Brain Res. 1992 Feb 14;572(1-2):281-5.

PMID:
1611524
15.
16.

Chronic treatment with ethanol alters the physiological action of nicotine.

Majchrzak MJ, Dilsaver SC.

Prog Neuropsychopharmacol Biol Psychiatry. 1992 Jan;16(1):107-15.

PMID:
1557502
17.

A nicotinic receptor antagonist enhances the hypothermic response to a muscarinic agonist.

Dilsaver SC, Majchrzak MJ, Snider RM, Davidson RK.

Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(4):539-49.

PMID:
1749830
18.

The effects of morphine on diet selection are dependent upon baseline diet preferences.

Gosnell BA, Krahn DD, Majchrzak MJ.

Pharmacol Biochem Behav. 1990 Oct;37(2):207-12.

19.

The anorectic effects of CRH and restraint stress decrease with repeated exposures.

Krahn DD, Gosnell BA, Majchrzak MJ.

Biol Psychiatry. 1990 May 15;27(10):1094-102.

20.

Effects of preferential delta and kappa opioid receptor agonists on the intake of hypotonic saline.

Gosnell BA, Majchrzak MJ, Krahn DD.

Physiol Behav. 1990 Mar;47(3):601-3.

21.

Effects of placebo (saline) injections on core temperature in the rat.

Dilsaver SC, Majchrzak MJ.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):417-22.

22.

Chronic treatment with ethanol produces supersensitivity to oxotremorine.

Majchrzak MJ, Dilsaver SC.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):379-86.

23.

Relationship between nicotine tolerance questionnaire scores and plasma cotinine.

Pomerleau CS, Pomerleau OF, Majchrzak MJ, Kloska DD, Malakuti R.

Addict Behav. 1990;15(1):73-80.

24.

Telemetric measurement of core temperature in pharmacological research: validity and reliability.

Dilsaver SC, Majchrzak MJ, Alessi NE.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(4):591-6.

25.
26.

Bright light blocks amitriptyline-induced cholinoceptor supersensitivity.

Dilsaver SC, Majchrzak MJ, Flemmer D.

Biol Psychiatry. 1989 Aug;26(4):416-23. No abstract available.

27.

Centrally administered opioid peptides stimulate saccharin intake in nondeprived rats.

Gosnell BA, Majchrzak MJ.

Pharmacol Biochem Behav. 1989 Aug;33(4):805-10.

28.

Paced puffing as a method for administering fixed doses of nicotine.

Pomerleau CS, Majchrzak MJ, Pomerleau OF.

Addict Behav. 1989;14(5):571-5.

29.

Nicotine dependence and the Fagerström Tolerance Questionnaire: a brief review.

Pomerleau CS, Majchrzak MJ, Pomerleau OF.

J Subst Abuse. 1989;1(4):471-7. Review.

PMID:
2485293
30.

Effects of bright light on adrenergic and cholinergic systems.

Majchrzak MJ, Dilsaver SC.

Am J Psychiatry. 1988 Dec;145(12):1608. No abstract available.

PMID:
3195686
31.

Doxepin-induced cardiac dysrhythmia.

Meador-Woodruff JH, Majchrzak MJ.

J Clin Psychopharmacol. 1988 Apr;8(2):144-5. No abstract available.

PMID:
2453531
32.

Chronic treatment with amitriptyline produces supersensitivity to nicotine.

Dilsaver SC, Majchrzak MJ, Alessi NE.

Biol Psychiatry. 1988 Jan 15;23(2):169-75.

33.

Bright artificial light produces subsensitivity to nicotine.

Dilsaver SC, Majchrzak MJ.

Life Sci. 1988;42(2):225-30.

34.

Bright artificial light produces subsensitivity to clonidine.

Dilsaver SC, Majchrzak MJ.

Life Sci. 1988;42(5):597-601.

35.

Bright artificial light subsensitizes a central muscarinic mechanism.

Dilsaver SC, Majchrzak MJ.

Life Sci. 1987 Dec 14;41(24):2607-14.

36.

Decrease in core temperature as an indication of cholinergic overdrive during amitriptyline withdrawal.

Dilsaver SC, Majchrzak MJ.

Biol Psychiatry. 1987 Dec;22(12):1485-7. No abstract available.

37.

Supplemental Content

Loading ...
Support Center